In summary, we have shown that LpX is remodeled by LCAT and apoA-I and that LpX alone is sufficient to induce many of the renal pathologic features seen in FLD renal disease, and hence may be a suitable biomarker for monitoring the response to any new therapy for FLD, such as recombinant LCAT. This evidence concerns the gene APOA1 and kidney disorder.